Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Adamis Pharmaceuticals

12 Health Care Stocks Moving In Thursday's Intraday Session

Why Cango Shares Are Trading Higher; Here Are 27 Stocks Moving Premarket

Why Cango Shares Are Trading Higher; Here Are 27 Stocks Moving Premarket

Gainers Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) rose 43.2% to $0.2097 in pre-market trading after jumping over 16% on Tuesday. Adamis Pharmaceuticals recently announced a review of strategic alternatives.

Recap Of Friday's Biotech Catalysts - End of The Day Summary

Recap Of Friday's Biotech Catalysts - End of The Day Summary

The U.S. Food and Drug Administration (FDA) has approved Arcutis Biotherapeutics’ (NASDAQ:ARQT) New Drug Application (NDA) for ZORYVE (roflumilast) cream 0.3% for the treatment of plaque psoriasis in patients 12 years of age or older. The company expects commercial launch of the product in Mid-August. Arcutis shares traded in a range of…

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Adamis Pharmaceuticals's Return On Capital Employed Overview

Adamis Pharmaceuticals (NASDAQ:ADMP) brought in sales totaling $1.16 million during Q1 according to data provided by Benzinga Pro. However, earnings decreased 18.01%, resulting in a loss of $10.35 million.

Adamis Pharmaceuticals's Earnings Outlook

Adamis Pharmaceuticals (NASDAQ:ADMP) is set to give its latest quarterly earnings report on Thursday, 2022-03-31. Here's what investors need to know before the announcement. Analysts estimate that Adamis Pharmaceuticals will report an earnings per share (EPS) of $-0.04.

Adamis Pharma Recalls Allergy Treatment Symjepi For Potential Manufacturing Defect

Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) voluntarily recalls certain lots of Symjepi (epinephrine) Injection 0.15 mg and 0.3 mg pre-filled single-dose syringes to the consumer level. The batches are being recalled due to the potential clogging of the needle preventing the dispensing of epinephrine. US WorldMeds (USWM) exclusively markets and distributes Symjepi in the U.S.,…

12 Health Care Stocks Moving In Monday's After-Market Session

Gainers Allarity Therapeutics (NASDAQ:ALLR) stock rose 25.3% to $2.84 during Monday's after-market session. The market value of their outstanding shares is at $22.9 million.

inkl

Read news from The Economist, FT, and more,
with one subscription

Organisations

European Commission

Bristol Myers Squibb

US Food and Drug Administration

Enanta Pharmaceuticals

Meridian Bioscience

ViiV Healthcare

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Topics

inkl

Read news from The Economist, FT, and more,
with one subscription

Places

255,689 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play